Parker Moss to Join Exscientia as EVP, Corporate Development
2023年10月17日 - 8:00PM
ビジネスワイヤ(英語)
Renowned technology champion to strengthen
company’s development of precision medicine and clinical innovation
platforms
Exscientia plc (Nasdaq: EXAI) today announced the appointment of
Parker Moss as Executive Vice President, Corporate Development,
effective January, 2024. In this newly established role, Parker
will lead the creation and execution of a focused corporate
development strategy to strengthen further and create new market
opportunities for the company’s precision medicine, clinical and
tech innovation platforms, with a particular focus on oncology.
Reporting to CEO Andrew Hopkins, he will help the company’s
Executive Leadership Team to identify and shape new business
opportunities, collaborations and strategic partnerships to
maximise the value of Exscientia’s patient-first AI technology
platforms.
Parker Moss will join Exscientia from Genomics England, a
company owned by the UK Department of Health & Social Care
which delivered the 100,000 Genomes Project in partnership with the
NHS and now supports the provision of whole genome sequencing
diagnostics in cancer and rare disease, and enables academic and
biopharma research in these fields. As Genomics England’s Chief
Partnerships Officer, he is currently responsible for strategic
partnerships in the biopharma sector and the wider healthcare and
technology ecosystem. Parker is also the co-lead of Genomics
England’s research programme in cancer and rare disease.
Previously, he was an entrepreneur in residence at F-Prime and
Eight Roads, Fidelity-backed VC funds, where he led an investment
in, and joined the executive team of the AI biotech company, Owkin.
He was a technology executive at Great Ormond Street Children’s
Hospital and at Virgin Care in the UK.
Parker also holds several non-executive roles, including on the
Cancer Research Horizons board (a company wholly owned by Cancer
Research UK). He was previously a member of the UK Secretary of
State for Health’s technology advisory board. Parker holds a
Natural Sciences degree in Physics and Philosophy from Durham
University.
“To deliver on our strategy of patient-first AI to develop the
best medicines for the right patients, the right strategic
partnerships are of critical value,” said Professor Andrew Hopkins
FRS FMedSci, founder and Chief Executive Officer of Exscientia.
“I’m thrilled that Parker, with his deep expertise and strong
global networks, has decided to join our team as we are on the
brink of further evolving our precision medicine and clinical
innovation platforms into new areas and markets.”
About Exscientia Exscientia is an AI-driven precision
medicine company committed to discovering, designing and developing
the best possible drugs in the fastest and most effective manner.
Exscientia developed the first-ever functional precision oncology
platform to successfully guide treatment selection and improve
patient outcomes in a prospective interventional clinical study, as
well as to progress AI-designed small molecules into the clinical
setting. Our internal pipeline is focused on leveraging our
precision medicine platform in oncology, while our partnered
pipeline broadens our approach to other therapeutic areas. By
pioneering a new approach to medicine creation, we believe the best
ideas of science can rapidly become the best medicines for
patients.
For more information visit us on https://www.exscientia.ai or
follow us on Twitter @exscientiaAI.
Forward-Looking Statements This press release contains
forward-looking statements as that term is defined in the Private
Securities Litigation Reform Act of 1995. Such statements are
subject to a number of risks, uncertainties and assumptions. In
light of these risks and uncertainties, and other risks and
uncertainties that are described in the Risk Factors section and
other sections of Exscientia’s Annual Report on Form 20-F, filed
with the Securities and Exchange Commission (SEC) on March 23, 2022
(File No. 001-40850), and other filings that Exscientia makes with
the SEC from time to time (which are available at
https://www.sec.gov/), the events and circumstances discussed in
such forward-looking statements may not occur, and Exscientia’s
actual results could differ materially and adversely from those
anticipated or implied thereby. Although Exscientia’s
forward-looking statements reflect the good faith judgement of its
management, these statements are based only on facts and factors
currently known by the Company. As a result, you are cautioned not
to rely on these forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231012133441/en/
Investor Relations: Sara Sherman
investors@exscientia.ai
Media: Oliver Stohlmann media@exscientia.ai
Exscientia (NASDAQ:EXAI)
過去 株価チャート
から 4 2024 まで 5 2024
Exscientia (NASDAQ:EXAI)
過去 株価チャート
から 5 2023 まで 5 2024